TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
January 07 2022 - 5:00PM
https://investors.tcr2.com/
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a
clinical-stage cell therapy company with a pipeline of novel T cell
therapies for cancer patients suffering from solid tumors, today
announced that Garry Menzel, President and Chief Executive Officer
of TCR2 Therapeutics, will present an update on Company progress at
the 40th Annual J.P. Morgan Healthcare Conference on Thursday,
January 13, 2022 at 7:30AM E.T. using a virtual platform.
A live webcast of the presentation will be
available on the Investors page of the Company’s website at
www.investors.tcr2.com. An archived replay will be available for at
least 30 days following the presentation.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for cancer patients suffering from solid
tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contacts:
TCR2
Therapeutics
Carl MauchDirector, Investor Relations and Corporate
Communications(617) 949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024